Immunomedics makes $10 million placement
Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, announced last week that it has sold $10 million inconvertible preferred stock to international investors. The investorscan convert the stock into shares of common stock over
Monoclonal antibody imaging agent developer Immunomedics of Morris
Plains, NJ, announced last week that it has sold $10 million in
convertible preferred stock to international investors. The investors
can convert the stock into shares of common stock over the next
two years.